[The effect of co-dergocrine mesylate on erythrocyte deformability of hyperosmolar blood in vitro].
Addition of low doses of co-dergocrine mesilate (CAS 8067-24-1), a drug containing a mixture of hydrated ergot alkaloids to hyperosmolar blood in vitro leads to a dose-dependent increase in erythrocyte filterability through a 8 mu filter system. The concentrations of co-dergocrine mesilate used in the present experiments ranged from 0.04675-6.0 mg/100 ml blood. Blood samples were incubated for 90 min at 37 degrees C, measuring temperature was 37 degrees C. It could be shown that the drug-induced increase in erythrocyte filterability was not dependent on the presence of leucocytes. At higher osmolarity values, when the erythrocytes were more rigid, higher concentrations of codergocrine mesilate were needed in order to obtain a comparable improvement in red cell deformability.
Ehrly
A M
AM
Klinikum der Johann Wolfgang Goethe-Universität, Abteilung Angiologie, Frankfurt/Main.
Saeger-Lorenz
K
K
D004877:Ergoloid Mesylates / Q000494:pharmacology*; D004907:Erythrocyte Deformability / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D012462:Saline Solution, Hypertonic
D012462:Saline Solution, Hypertonic; D004877:Ergoloid Mesylates
Beeinflussung der Erythrozyten-Verformbarkeit hyperosmolaren Blutes in vitro durch Co-Dergocrinmesilat.